Yaron Werber predicts BioNTech will report phase three stage 2 data for CTLA-4 in second-line squamous lung cancer showing survival benefit vs. docetaxel.
“they have second line squamous lung cancer data with their CTLA four that's looked very good in an interim showing survival against docetaxel. Docetaxel, as we all know, has been a very tough drug to beat historically, so we're all gonna be looking at the the next stage two of that phase three.”
→ Read the source episode
Our resolution criterion
disputableBioNTech announces phase three stage 2 results for CTLA-4 in second-line squamous lung cancer with survival data vs. docetaxel
More from Biotech Hangout
Tarsus Pharmaceuticals' Alkias phase three Northstar study for gilderretinol will report data in H2 2029.
Ten X will meet with EMA to explore enriched patient populations for HFpEF drug following failed phase three.
Brian Skorney predicts Lilly's Lp(a) CVOT data may read out in 2029.
Daphne Zohar predicts Heidi Overton's FDA commissioner confirmation hearings will occur after the Senate summer recess.
Eric Schmidt predicts the HARMONY three study for evanesquimab will read out positively in 6-9 months.
Paul Matisse reports Biohaven's KV7 epilepsy drug is on partial clinical hold with phase 3 data coming soon.
Summaries are ours; the quote is a verbatim transcript excerpt. Our resolution criteria are editorial and disputable. How this works.